TABLE 4.
Summary of publications* on cytokines and/or chemokines in MARS therapy
|
Outcomes post-MARS therapy
|
|||||
|---|---|---|---|---|---|
| Author (reference), year | Country | n | Etiology | Biochemical | Pruritus |
| Lisboa et al (present), 2012 | Canada | 3 | PBC (n=2), BRIC (n=1) | ↓Bile acids, bilirubin, urea | Improvement in 3/3 |
| Leckie et al (30), 2012 | UK | 15 | PBC (n=11), PSC (n=3), Other (n=1) | ↓Bilirubin, ALT, ALP, creatinine | Improvement in 13/15 |
| Pares et al (31), 2010 | Spain | 20 | PBC (n=10), PSC (n=1), Alagille syndrome (n=1), OLT graft rejection (n=8) | ↓Bile acid, bilirubin, GGT, cholesterol | Improvement in 19/20 |
| Lemoine et al (32), 2008 | France | 1 | PFIC3 (n=1) | ↓Bile acids | Improvement in 1/1 |
| Silvagni et al (33), 2008 | Italy | 1 | Drug-induced + Turner syndrome (n=1) | ↓Bile acid | Improvement in 1/1 |
| Novelli et al (34), 2006 | Italy | 9 | HCV (n=9) | ↓Bile acid, bilirubin, creatinine | Improvement in 9/9 |
| Montero et al (35), 2006 | Spain | 3 | PBC/AIH (n=1), post-OLT cholestasis (n=1), post-OLT HCV recurrence (n=1) | ↓Bilirubin | Improvement 4/4 |
| Saich et al (36), 2005 | UK | 1 | BRIC (n=1) | ↓Bile acids | Improvement in 1/1 |
| Ribo et al (37), 2005 | Spain | 2 | post-OLT cholestasis (n=2) | ↓Bilirubin | Improvement in 2/2 |
| Bellmann et al (38), 2004 | Austria | 2 | Drug-induced (n=2) | ↓Bile acids, bilirubin | Improvement in 2/2 |
| Pares et al (39), 2004 | Spain | 4 | PBC (n=4) | ↓Bile acids | Improvement in 4/4 |
| Bellmann et al (40), 2004 | Austria | 7 | post-OLT cholestasis (n=7) | ↓Bile acid, AST, GGT | Improvement in 6/7 |
| Macia et al (41), 2003 | Spain | 3 | post-OLT cholestasis (n=1), PBC (n=2) | ↓Bilirubin, urea, creatinine | Improvement in 3/3 |
| Doria et al (42), 2003 | Italy | 3 | HCV (n=3) | ↓Bile acid | Improvement in 3/3 |
| Sturm et al (43), 2002 | France | 1 | BRIC (n=1) | ↓Bile salts, bilirubin | Improvement in 1/1 |
Only English language, nonduplicated publications measuring cytokines or chemokines in the blood of patients receiving MARS therapy were included.
Increased;
Decreased; ACLF Acute-on-chronic liver failure; AIH Autoimmune hepatitis; ALF Acute liver failure; ALT Alanine aminotransferase; ALP Alkaline phosphatase; AST Aspartate aminotransferase; BRIC Benign recurrent intrahepatic cholestasis; GGT Gamma-glutamyl transpeptidase; HBV Hepatitis B virus; HCV Hepatitis C virus; HEV Hepatitis E virus; HRS Hepatorenal syndrome; MARS Molecular adsorbent recirculating system; NASH Nonalcoholic steatohepatitis; OLT Orthotopic liver transplantation; PBC Primary biliary cirrhosis; PFIC Progressive familial intrahepatic cholestasis; PSC Primary sclerosing cholangitis; UK United Kingdom